Drugs / JLP-2002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04914221 | Mar → May 2021 | overactive bladder | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04917315 | May 2020 → Aug 2021 | overactive bladder | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Jeil Pharmaceutical Co., Ltd. | Regulatory 제일약품, 과민성방광치료제 ‘베오바정’ 허가 승인 jeilpharm.co.kr ↗
제일약품(대표 성석제)은 과민성방광치료 신약 ‘베오바정50밀리그램(비베그론)’ 을 식품의약품안전처로부터 허가승인 받았다고 1일 밝혔다. |
| 2022-04-01 | Jeil Pharmaceutical Co., Ltd. | Regulatory 제일약품, 과민성방광치료제 ‘베오바정’ 품목허가 신청 jeilpharm.co.kr ↗
제일약품(대표 성석제)은 과민성방광치료 신약 ‘베오바정’의 품목허가신청을 완료했다고 25일 밝혔다. |
| 2020-05-22 | Jeil Pharmaceutical Co., Ltd. | Regulatory 제일약품, 과민성방광신약 ''비베그론'' 국내 임상3상 승인 jeilpharm.co.kr ↗
식약처는 21일제일약품이 신청한 ''비베그론(vibegron)''에 대한 임상3상시험계획서(IND)를 승인했다. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Jeil Pharmaceutical Co., Ltd. | 제일약품, 과민성방광치료제 ‘베오바정’ 허가 승인 jeilpharm.co.kr ↗ |
| 2022-04-01 | Jeil Pharmaceutical Co., Ltd. | 제일약품, 과민성방광치료제 ‘베오바정’ 품목허가 신청 jeilpharm.co.kr ↗ |
| 2020-05-22 | Jeil Pharmaceutical Co., Ltd. | 제일약품, 과민성방광신약 ''비베그론'' 국내 임상3상 승인 jeilpharm.co.kr ↗ |
| 2019-11-07 | Jeil Pharmaceutical Co., Ltd. | 제일약품, 교린社의 과민성방광 치료제 ‘비베그론(vibegron)’ 국내 독점 판매 계약 체결 jeilpharm.co.kr ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLP-2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04917315 ↗ |
| Known as | vibegron | “administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.” NCT04917315 ↗ |
| Action | Activate | “JLP-2002, a beta 3-adrenergic receptor (β3-AR) agonist” NCT04917315 ↗ |
| Route | Oral | “following oral administration of JLP-2002” NCT04914221 ↗ |